Making ALS Advocacy My Purpose

Chris was diagnosed with ALS in 2024. Before that, he spent 40 years in the oil and gas industry, working and living in eight countries across five continents. He’s dedicated himself to helping others with ALS move forward. This content is sponsored by Tanabe Pharma America, Inc. (TPA) and is…

People with amyotrophic lateral sclerosis (ALS) who were exposed to smoke from wildfires prior to developing the disease are more than twice as likely to experience respiratory failure or death, according to a new analysis. The findings underscore the need for further research to understand how air pollution and…

The ALS Network will continue to host its ASK ME webinar series throughout 2026, featuring expert-led sessions on advocacy, care, research, and daily life with amyotrophic lateral sclerosis (ALS). This…

A specific alteration in the TDP-43 protein can reduce the viability of nerve cells in a lab model of amyotrophic lateral sclerosis (ALS), causing problems with energy generation and molecular transport within the cell, a new study finds. Notably, however, researchers found that this mutation does not cause TDP-43 protein…

There are both big and little losses that come with ALS, for the person with the disease and their family. Each stage of the disease brings something new to grieve. When my husband, Todd, was diagnosed in 2010, one of our biggest losses was the future that we…

Scientists have developed a way to deliver a nerve-protecting substance past the brain’s natural defenses using fat-based ‘bubbles,’ a strategy that significantly extended survival and preserved movement in mouse models of amyotrophic lateral sclerosis (ALS). This approach, called talineuren, successfully delivered the protective molecule GM1 directly to damaged motor…

“I don’t want to go to the doctor,” I said. “What if it’s something bad?” “What are you afraid of? What’s the worst it could be?” my wife replied. “ALS …” That was the first time I said those three letters out loud — half joking, half hoping that…

Dosing has begun in a new arm of the HEALEY ALS platform trial, with Regimen I — the ninth — testing NUZ-001, an oral small molecule developed by Neurizon Therapeutics to slow declines in function and extend survival in people with amyotrophic lateral sclerosis (ALS). As a platform…

Next week, researchers, clinicians, industry leaders, and families will gather at the 2026 MDA Clinical & Scientific Conference, hosted by the Muscular Dystrophy Association (MDA), to discuss the latest advances in neuromuscular disease research and care. Ahead of the event, Bionews, the parent company of this site, sat…

Blood levels of lactate — a molecule involved in how the body produces energy — may help predict survival and short-term weight changes in people with amyotrophic lateral sclerosis (ALS), according to a new study from Australia and Japan. Researchers found that patients with lower blood lactate levels had…